
Theravance Biopharma (TBPH) Stock Forecast & Price Target
Theravance Biopharma (TBPH) Analyst Ratings
Bulls say
Theravance Biopharma has reported a total revenue of $18.8 million in the fourth quarter, reflecting an 8% year-over-year increase, supported by a substantial growth in hospital doses, which surged 49% year-over-year and 26% quarter-over-quarter. The strong sales performance of YUPELRI, driven by notable hospital account growth, indicates a robust trajectory for future financial performance. With a focus on winning therapeutic interchange and potential additional revenues from upcoming approvals, the company's strategic emphasis on organ-selective medicines in inflammation and immunology positions it well for sustained growth.
Bears say
Theravance Biopharma reported a non-GAAP loss per share of $0.05, which fell short of both the company's internal estimate and broader street consensus, raising concerns about its financial performance. The company also experienced a significant loss on extinguishment of debt amounting to $3,034, suggesting potential financial strain and mismanagement of its debt obligations. Furthermore, the uncertainty surrounding future revenue generation post-loss of exclusivity (LOE) for its products, coupled with challenges related to the development of generic alternatives for its triple-combination DPI, contributes to a negative outlook on the stock's future performance.
This aggregate rating is based on analysts' research of Theravance Biopharma and is not a guaranteed prediction by Public.com or investment advice.
Theravance Biopharma (TBPH) Analyst Forecast & Price Prediction
Start investing in Theravance Biopharma (TBPH)
Order type
Buy in
Order amount
Est. shares
0 shares